A5007202804- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Mesenchymal stem cell research
- Transplantation: Methods and Outcomes
- Cytomegalovirus and herpesvirus research
- Neutropenia and Cancer Infections
- Blood groups and transfusion
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Hemoglobinopathies and Related Disorders
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- COVID-19 Clinical Research Studies
- Erythrocyte Function and Pathophysiology
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood disorders and treatments
- Neonatal Respiratory Health Research
Churchill Hospital
2016-2025
University of Oxford
2016-2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2017-2025
Fundação Pró-Sangue Hemocentro de São Paulo
2017-2025
Instituto do Câncer do Estado de São Paulo
2012-2025
Universidade de São Paulo
2016-2025
Universidade Federal da Bahia
2005-2025
Hospital Sírio-Libanês
2015-2024
Hôpital Saint-Louis
2015-2024
Assistance Publique – Hôpitaux de Paris
2014-2024
Cord-blood banks have increased the use of cord-blood transplantation in patients with hematologic disorders. We established a registry containing information on outcome transplantation.
Promising results of cord-blood transplants from unrelated donors have been reported in adults.We compared outcomes 682 adults with acute leukemia who received a hematopoietic stem-cell transplant an donor: 98 cord blood and 584 bone marrow. The transplantations were performed 1998 through 2002 to Eurocord the European Blood Marrow Transplant Group.Recipients younger than recipients marrow (median, 24.5 vs. 32 years age; P<0.001), weighed less 58 68 kg; had more advanced disease at time...
Umbilical-cord blood as an alternative to bone marrow for hematopoietic stem-cell transplantation may lower the risk of graft-versus-host disease (GVHD).
Attack rate in Manaus Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked Manaus, Brazil, May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors São Paulo, noted when transmission began to fall, estimated final attack rates October (see Perspective by Sridhar Gurdasani). Heterogeneities immune protection, population structure, poverty, modes of public...
To evaluate the role of donor lymphocyte infusion (DLI) in treatment relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).We retrospectively analyzed data 399 patients with AML first hematological relapse HSCT whose did (n = 171) or not 228) include DLI. After correction for imbalances and established risk factors, two groups were compared respect to overall survival. Further, a detailed analysis factors survival among DLI recipients was...
Abstract BACKGROUND: It was investigated whether the European Group for Blood and Marrow Transplantation risk score, previously established chronic myeloid leukemia, could be used to predict outcome after allogeneic hematopoietic stem cell transplantation (HSCT) hematological disease in general. METHODS: Age of patient, stage, time interval from diagnosis transplant, donor type, donor‐recipient sex combination were establish a score 0 7 points. Its validity tested 56,505 patients, 33,113...
Thalassemia major and sickle cell disease are the two most widely disseminated hereditary hemoglobinopathies in world. The outlook for affected individuals has improved recent years due to advances medical management prevention treatment of complications. However, hematopoietic stem transplantation is still only available curative option. use been increasing, outcomes today have substantially compared with past three decades. Current experience world-wide that more than 90% patients now...
Purpose T-cell-replete HLA-haploidentical donor hematopoietic transplantation using post-transplant cyclophosphamide was originally described bone marrow (BM). With increasing use of mobilized peripheral blood (PB), we compared transplant outcomes after PB and BM transplants. Patients Methods A total 681 patients with hematologic malignancy who underwent in the United States between 2009 2014 received (n = 481) or 190) grafts. Cox regression models were built to examine differences by graft...
Purpose Reduced intensity conditioning regimen (RIC) is increasingly used in hematopoietic stem cell transplantation (HSCT). Unrelated donor (UD) transplants have more complications. We wanted to examine if RIC a valid treatment option using UD acute myeloblastic leukemia (AML). Patients and Methods Between 1999 2005, 401 patients with AML were treated 1,154 received myeloablative (MAC), reported the European Group for Blood Marrow Transplantation Registry. < ≥ 50 years of age analyzed...
Purpose Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication (FLT3/ITD) have poor prognosis if treated chemotherapy only. Whether this alteration also affects outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) remains uncertain. Methods We analyzed 206 patients who underwent HLA-identical sibling matched unrelated HSCTs reported to the European Group for Blood Marrow Transplantation a diagnosis of AML normal cytogenetics data on FLT3/ITD...
Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increasingly used in patients lacking HLA-matched sibling donors (MSD). We compared outcomes after Haplo-HCT PT-Cy with MSD-HCT lymphoma, the Center for International Blood and Marrow Transplant Research registry.We evaluated 987 adult undergoing either (n = 180) or 807) following reduced-intensity conditioning regimens. The group received graft-versus-host...
Importance In newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits and all single-mutation variants, including T315I. Objective To compare frontline ponatinib vs imatinib in adults with Ph+ ALL. Design, Setting, Participants Global registrational, phase 3, open-label trial aged 18 years older From January 2019 May...
Mesenchymal stem cells (MSCs) give origin to the marrow stromal environment that supports hematopoiesis. These present a wide range of differentiation potentials and complex relationship with hematopoietic (HSCs) endothelial cells. In addition bone (BM), MSCs can be obtained from other sites in adult or fetus. We isolate umbilical cord (UC) veins are morphologically immunophenotpically similar BM. culture, these capable differentiating vitro into adipocytes, osteoblasts, condrocytes. The...